Catalytic asymmetric synthesis and anticancer effects of the novel non-calcemic analog of vitamin D, 2α-fluoro-19-nor-22-oxa-1α,25-dihydroxyvitamin D3 in metastatic lung carcinoma |
| |
Authors: | Kimie Nakagawa Keiichi Ozono Noboru Kubodera Yoshimitsu Itoh |
| |
Affiliation: | a Department of Hygienic Sciences, Kobe Pharmaceutical University, Kobe 658-8558, Japan b Department of Developmental Medicine, Pediatrics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan c Institute of Molecular and Cellular Bioscience, University of Tokyo, Tokyo 113-0032, Japan d Chugai Pharmaceutical Co. Ltd., Tokyo 104-8301, Japan e Department of Applied Chemistry, Tokyo Institute of Technology, Tokyo 152-8552, Japan |
| |
Abstract: | 1α,25-Dihydroxyvitamin D3 (1α,25-D3) has potent antiproliferative and anti-invasive properties in vitro in cancer cells. However, the major limitation to its clinical use is that it causes hypercalcemia. Therefore, vitamin D analogs with potent cell regulatory effects but with weaker calcemic effects than 1α,25-D3 are required. Among them, 22-oxa-1α,25-D3 and 19-nor-1α,25-D3 have anti-cancer effects with relatively low calcemic effects. Modifications at the C-2α position of the A-ring also produced analogs with a unique biological profile. Not only the side-chain but also the A-ring modification thus generates a unique analog with potent cell regulatory effects and low calcemic activity as well. We report here that the hybrid 1α,25-D3 analog, synthesized via the highly regio- and stereo-selective ring opening 2α-fluorination and catalytic asymmetric carbonyl-ene cyclization, with 2α-fluoro, 19-nor, and 22-oxa modification exhibits unique cell regulatory activities against the development of metastatic lung carcinoma. |
| |
Keywords: | 2α-F-19-nor-22-oxa-1α,25-D3 Non-calcemic Lung cancer Metastasis |
本文献已被 ScienceDirect 等数据库收录! |
|